Next 10 |
home / stock / tcon / tcon articles
Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for i...
Shares of Streamline Health Solutions, Inc. (NASDAQ:STRM) fell sharply during Wednesday's session after the company reported worse-than-expect...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Wednesday. Following the market opening Wednesday,...
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a c...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers repo...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...
Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its...
Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. A...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...
News, Short Squeeze, Breakout and More Instantly...
TRACON Pharmaceuticals Inc. Company Name:
TCON Stock Symbol:
OTCMKTS Market:
TRACON Pharmaceuticals Inc. Website:
Kroger Company (The) (KR) is expected to report $0.98 for Q3 2025 Comera Life Sciences Holdings Inc. (CMRA) is expected to report for Q3 2024 Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2025 Canadian Imperial Bank of Commerce (CM) is expected to rep...
CURO Group Holdings Corp. (CUROQ) is expected to report for Q3 2024 Audacy, Inc. (AUDAQ) is expected to report for Q3 2024 Enviva Inc. (EVVAQ) is expected to report for Q3 2024 Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.11 for Q3 2024 Better Therapeutics Inc...